P. Swift

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

K. Y. Wong, Mohammad A. Qayum, John S. Clouston, 2022, Lancet.

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

K. Y. Wong, Beverley E. Crane, Scott M Elliott, 2021, Lancet.

Effects of Empagliflozin on Progression of Chronic Kidney Disease: A Pre-Specified Secondary Analysis from the Empa-Kidney Trial

M. Seman, T. Miyatsuka, Y. Lee-Barkey, 2023, The lancet. Diabetes & endocrinology.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

M. Seman, T. Miyatsuka, Y. Lee-Barkey, 2023, The lancet. Diabetes & endocrinology.